Hims & Hers pushes beyond weight loss with Peptides+, a line of compounded longevity treatments
Hims & Hers Health (HIMS) launched Peptides+ on Wednesday, a service that prescribes compounded peptide and longevity treatments after a visit with a licensed provider.
Customers can get up to five treatments at launch, as their provider decides:
- Sermorelin, which prompts the body to release growth hormone
- NAD+, a coenzyme cells need to make energy and fix DNA
- Glutathione, an antioxidant the body makes on its own
- Vitamin B12
- L-Carnitine, which helps the body burn fat for energy
None of the five compounded versions has approval from the Food and Drug Administration (FDA). Hims says the law allows them, and that they come from U.S. pharmacies that state boards license and inspect.
The launch follows an October policy from the Department of Health and Human Services. Under it, the FDA will hold off on action against licensed pharmacies that make six unapproved peptides while it writes formal rules. The policy does not approve those peptides.
Hims Chief Medical Officer Anant Vinjamoori told CNBC the company is still learning how best to use them: "We don't have all of this data that we're used to having with compounds like this." He said people with serious heart, liver or kidney disease will not be candidates for now.
Tufts University chemistry professor Joshua Kritzer said that without testing, "all you have is anecdotal information."
Peptides+ can be paired with Care+, which adds lab tests twice a year and round-the-clock messaging with providers.
An early access list Hims opened in late October drew more than 10,000 sign-ups in 15 days, a company spokesperson told CNBC.
Hims bought a peptide plant in California in February 2025. On its third-quarter earnings call, the company said that plant lets it make key peptides in the U.S., which it believes sets its offer apart.
Two more peptides, BPC-157 and TB-500, will follow "consistent with regulatory standards," the company says. Most studies of both have been done in animals.
Sources & Further Reading
- "Hims & Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health." Hims & Hers. November 18, 2026.
- "Hims & Hers launches new peptide treatments โ while admitting there's more to learn about efficacy." CNBC. November 18, 2026.
- "Hims & Hers Health (HIMS) Q3 2026 Earnings Call Transcript." Stock Analysis. November 9, 2026.
This article was drafted with the help of AI. Kyle Vallans fact-checked, edited and published the article and is responsible for its accuracy and quality. How we use AI